Focus on the cetirizine use in clinical practice: a reappraisal 30 years later

• Review
• Open Access

• Multidisciplinary Respiratory Medicine

• Angelo G. Corsico, 
• Salvatore Leonardi, 
• Amelia Licari, 
• Gianluigi Marseglia, 
• Michele Miraglia del Giudice, 
• Diego G. Peroni, 
• Carmelo Salpietro & 
• Giorgio Ciprandi 

volume 14, Article number: 40 (2019) 

Abstract

Antihistamines are currently one of the most commonly administered categories of drugs. They are used to treat symptoms that are secondary to histamine release, which is typical of certain allergic conditions, including rhinitis, conjunctivitis, asthma, urticaria, and anaphylaxis. Cetirizine belongs to the second-generation family, so, it is very selective for peripheral H1 receptors, is potent and quickly relieves symptoms, exerts additional anti-allergic/anti-inflammatory effects, and is usually well-tolerated. It has been marketed 30 years ago. In these years, a remarkable body of evidence has been built. The current review provides a practical update on the use of cetirizine in clinical practice.

Download PDF

Allergic or Pseudo-Allergic Gastrointestinal Disorders Free Access Eosinophilic Gastrointestinal Diseases in Childhood

	Koutri E. · Papadopoulou A. Author affiliations Division on Gastroenterology, Hepatology and Nutrition, First Department of Pediatrics, University of Athens, Children’s Hospital “Agia Sofia”, Athens, Greece

Ann Nutr Metab 2018;73(suppl 4):18–28

https://doi.org/10.1159/000493668

Abstract

Eosinophilic gastrointestinal diseases (EGIDs) comprise a group of chronic, inflammatory diseases of the gastrointestinal (GI) tract, that are characterized, clinically, by symptoms related to the dysfunction of the involved segment(s) of the GI tract, and histologically, by dense eosinophilic inflammation, in the absence of an identifiable secondary cause. The group of EGIDs comprises eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC). EoE is the most common and the best described EGID compared to EG, EGE, and EC.

Efficacy of the Enquiring About Tolerance (EAT) study among infants at high risk of developing food allergy

December 2019Volume 144, Issue 6, Pages 1606–1614.e2

Michael R. Perkin, PhDa

, 

Kirsty Logan, PhDb

, 

Henry T. Bahnson, MPHc

, 

Tom Marrs, PhDb

, 

Suzana Radulovic, MDb

, 

Joanna Craven, MPHb

, 

Carsten Flohr, PhDd

, 

E.N. Mills, PhDe

, 

Serge A. Versteeg, BScf

, 

Ronald van Ree, PhDf,g

, 

Gideon Lack, MB, BChb,∗,Correspondence information about the author MB, BCh Gideon LackEmail the author MB, BCh Gideon Lack

 on behalf of the 

 Enquiring About Tolerance (EAT) study team

 

Open Access

PlumX Metrics

DOI: https://doi.org/10.1016/j.jaci.2019.06.045

 |

Article Info

• Abstract

• Full Text

• Images
• References

Article Outline

1. Methods
   1. Participants
   2. EAT study intervention
   3. Eczema assessment
   4. Sensitization
   5. Primary outcome
   6. Statistical analyses
2. Results
   1. Eczema
   2. Ethnicity
   3. Sensitization
   4. Adherence to the early introduction regimen among groups at high risk of food allergy
   5. Efficacy of the early introduction regimen among groups at high risk of food allergy
      1. Enrollment eczema
      2. Ethnicity
      3. Infants sensitized at enrollment
3. Discussion
4. Discussion
5. References

Graphical abstract

View Large Image | View Hi-Res Image | Download PowerPoint Slide

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. A Phase 3 Randomized Clinical Trial

Original Investigation

Eric L. Simpson, MD¹; Amy S. Paller, MS, MD^2,3; Elaine C. Siegfried, MD⁴; et alMark Boguniewicz, MD⁵; Lawrence Sher, MD⁶; Melinda J. Gooderham, MD^7,8,9; Lisa A. Beck, MD¹⁰; Emma Guttman-Yassky, MD, PhD^11,12,13; David Pariser, MD¹⁴; Andrew Blauvelt, MD, MBA¹⁵; Jamie Weisman, MD¹⁶; Benjamin Lockshin, MD^17,18; Thomas Hultsch, MD¹⁹; Qin Zhang, PhD²⁰; Mohamed A. Kamal, PharmD, PhD²⁰; John D. Davis, PhD²⁰; Bolanle Akinlade, MD, MBA²⁰; Heribert Staudinger, MD, PhD²¹; Jennifer D. Hamilton, PhD²⁰; Neil M. H. Graham, MBBS, MD, MPH²⁰; Gianluca Pirozzi, MD, PhD²¹; Abhijit Gadkari, PhD²⁰; Laurent Eckert, PhD²²; Neil Stahl, PhD²⁰; George D. Yancopoulos, MD, PhD²⁰; Marcella Ruddy, MD²⁰; Ashish Bansal, MD²⁰

Author Affiliations Article Information

JAMA Dermatol. Published online November 6, 2019. doi: https://doi.org/10.1001/jamadermatol.2019.3336

Key Points

Question  What is the efficacy and safety of dupilumab monotherapy in adolescents with moderate to severe inadequately controlled atopic dermatitis?

Findings  In this randomized phase 3 clinical trial including 251 adolescents with moderate to severe atopic dermatitis, dupilumab 200 or 300 mg every 2 weeks and 300 mg every 4 weeks resulted in a significant treatment response vs placebo following 16-week treatment, with an acceptable safety profile.

Mechanism(s) of prolonged attenuation of allergic responses after modulation of idiotypic regulatory network

• Allergy, Asthma & Clinical Immunology Research
• Open Access
• 
  

• R. M. Gorczynski, 
• T. Maqbool & 
• G. Hoffmann 

Allergy, Asthma & Clinical Immunology volume 15, Article number: 79 (2019) 

• details

Abstract

Background

We showed previously that allergic reactivity to ovalbumin (OVA) could be regulated in mice following perturbation of immune networks using combinations of an immune Ig along with anti-idiotypic Ig. We have explored features of this regulation including: its persistence after cessation of administration of combined Igs; the ability of heterologous Igs to produce immunoregulation; a role for Treg induction in regulation; and the ability to attenuate responses in mice pre-sensitized to an allergic stimulus.

CME / ABIM MOC

Virtual Case Challenges: Inflammatory Skin Conditions and Comorbid Allergies 

• Authors: Jonathan I. Silverberg, MD, PhD, MPH; Jonathan Spergel, MD, PhD
• CME / ABIM MOC Released: 11/22/2019
• Valid for credit through: 11/22/2020

START ACTIVITY

• 

• Credits Available

  Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
  ABIM Diplomates - maximum of 1.00 ABIM MOC points

  You Are Eligible For

  • AMA PRA Category 1 Credit(s)™

Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis

Open Access

Charles P. Andrews, MD1,∗,Correspondence information about the author MD Charles P. AndrewsEmail the author MD Charles P. Andrews

, 

Dale Mohar, MD2

, 

Yacine Salhi, PhD3

, 

Sudeesh K. Tantry, PhD3

DOI: https://doi.org/10.1016/j.anai.2019.11.007

Article Info

• Abstract

• Full Text
• Images
• References

ABSTRACT

BACKGROUND

GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).

OBJECTIVE

To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR).

METHODS

In this phase 2, double-blind, parallel-group study, patients (≥12 years of age) with SAR were equally randomized to twice-daily GSP301 (olopatadine 665μg and mometasone 25μg), once-daily GSP301 (olopatadine 665μg and mometasone 50μg), twice-daily or once-daily olopatadine monotherapy (665μg), mometasone monotherapy (twice-daily 25μg or once-daily 50μg), or placebo for 14 days.

30 Years Of Sublingual Immunotherapy

REVIEW ARTICLE
Free Access

Giovanni Passalacqua , Diego Bagnasco , Giorgio Walter Canonica
https://doi.org/10.1111/all.14113

Abstract

Allergen Immunotherapy (AIT) was introduced in clinical practice on an empirical basis more than 100 years ago. Since the first attempts, AIT was administered subcutaneously. Indeed, other routes of administration were proposed and studied, in particular to improve the safety, but only the sublingual route (SLIT) achieved a credibility based on evidence, and was then accepted as a viable “alternative” option to the subcutaneous route. SLIT was largely used in clinical trials and clinical practice in this last 30 years. Thus, a large amount of data is available, coming from either controlled trials and post‐marketing surveillance studies.